Clinical trial NCT02172274: BI 10773 Administered as Oral Solution to Healthy Male Volunteers
Official title: A Phase I, Open-label, Single-dose Trial to Investigate the Metabolism and Pharmacokinetics of 50 mg [14C]-BI 10773 When Administered as Oral Solution to Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-06-24
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to determine the pharmacokinetics of BI 10773 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of \[14C\] BI 10773


Eligibility criteria: Inclusion Criteria:

* Healthy males according to a complete medical history, including a physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG (electrocardiogram), and clinical laboratory tests
* Age 18 to 55 years, inclusive
* Body mass index 18.5 to 29.9 kg/m2, inclusive
* Nonsmoker
* Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion Criteria:

* Any finding in the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
* Any evidence of a clinically relevant concomitant disease
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hormonal, psychiatric or neurological disorders (including all forms of epilepsy)
* Surgery of the gastrointestinal tract (except appendectomy)
* History of relevant orthostatic hypotension, fainting spells or blackouts
* Subjects with Gilbert's Syndrome
* Chronic or relevant acute infections
* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
* Intake of drugs with a long half-life (\>24 hours) within one month prior to administration of the trial drug
* Use of prescription medication, over-the-counter drugs or herbal preparations within 14 days prior to administration of the trial drug
* Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
* History or evidence of habitual tobacco or nicotine use within six months prior to administration of the trial drug
* Alcohol abuse (more than 60 g/day)
* Drug abuse in opinion of investigator
* Blood donation (more than 100 mL within four weeks prior to administration of trial drug or during the trial)
* Excessive physical activity within five days prior to administration of trial drug
* Any laboratory value outside the reference range that is of clinical relevance
* Inability to comply with dietary regimen of trial centre
* A marked baseline prolongation of QT/QTc interval (corrected QT interval)(e.g., repeated demonstration of a QTc interval \>450 ms)
* Male subjects must agree to minimise the risk of female partners becoming pregnant from the dosing day until three months after the completion of the study. Acceptable methods of contraception for male volunteers include a vasectomy no less than three months prior to dosing, barrier contraception, or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intrauterine device, tubal ligation, hormonal contraceptive for at least two months, or diaphragm with spermicide
* Participation in more than one other radiolabeled investigational drug trial within one year prior to administration of the trial drug. The previous radiolabeled trial drug must have been received more than six months prior to administration of the trial drug for this study, and the total exposure from this study and the previous study will be within the recommended levels considered safe, per 21 CFR (Code of Federal Regulations) 361.1 (eg, less than 5000 mrem whole body annual exposure)
* Irregular defecation pattern (less than one bowel movement a day)

Primary outcomes:
measure: Cmax (maximum concentration of the analyte in plasma)
timeFrame: pre-dose and up to 144 hours after administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma)
timeFrame: pre-dose and up to 144 hours after administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
timeFrame: pre-dose and up to 144 hours after administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity)
timeFrame: pre-dose and up to 144 hours after administration
measure: λz (terminal rate constant in plasma)
timeFrame: pre-dose and up to 144 hours after administration
measure: t1/2 (terminal half-life of the analyte(s) in plasma)
timeFrame: pre-dose and up to 144 hours after administration
measure: MRTpo (mean residence time of the analyte(s) in the body after oral administration)
timeFrame: pre-dose and up to 144 hours after administration
measure: CL/F (apparent/total clearance of the analyte(s) in plasma after an extravascular dose)
timeFrame: pre-dose and up to 144 hours after administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz after an extravascular dose)
timeFrame: pre-dose and up to 144 hours after administration
measure: feurine,0-tz (amount of analyte excreted in urine over the time interval from 0 to the time of the last quantifiable data point in % of dose, additionally excretion within each sampling interval will be calculated)
timeFrame: pre-dose and up to 168 hours after administration
measure: fefaeces,0-tz (amount of analyte excreted in faeces over the time interval from 0 to the time of the last quantifiable data point in % of dose, additionally excretion within each sampling interval will be calculated)
timeFrame: pre-dose and up to 168 hours after administration
measure: CLR,0-tz (renal clearance of analyte)
timeFrame: pre-dose and up to 168 hours after administration
measure: Individual concentration-time profiles of [14C] radioactivity in whole blood, plasma, urine, and faeces
timeFrame: up to 8 days
measure: Individual concentration-time profiles of BI 10773 in plasma and urine
timeFrame: up to 8 days
measure: Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces
timeFrame: up to 8 days
measure: Identification of major metabolites in urine, faeces, and plasma
timeFrame: up to 8 days
measure: Cblood cell/Cplasma ratio of [14C]-radioactivity
timeFrame: up to 8 days
measure: Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo
timeFrame: up to 8 days
Secondary outcomes:
measure: Number of patients with abnormal findings in physical examination
timeFrame: Baseline and within 6 days after discharge
measure: Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)
timeFrame: Baseline, days 1, 2, 7 and within 6 days after discharge
measure: Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)
timeFrame: Baseline, days 1, 2, 7 and within 6 days after discharge
measure: Number of patients with abnormal changes in laboratory parameters
timeFrame: Baseline, days 1, 2 and within 6 days after discharge
measure: Number of patients with adverse events
timeFrame: Up to 22 days
measure: Assessment of tolerability by investigator on a 4-point scale
timeFrame: Day 8
Other outcomes:
Locations:
Study officials:
References: